Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis

Sponsor
Novartis Pharmaceuticals
Study ID
NCT06431750
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
6 Years - 18 Years
Healthy Volunteers
Not accepted

Interventions

  • Secukinumab — OTHER
    This is an observational study, there is no treatment allocation.

Study Details

This is a multicenter, non-interventional, cohort study in pediatric patients with active juvenile enthesitis-related or psoriatic arthritis

Key Dates

Start date
Apr 30, 2025
Status verified
Jan 2025
Primary completion
Aug 30, 2028
Completion
Aug 30, 2028

Study Design

Enrollment
150 participants (estimated)

Arms

  • Arm: Secukinumab
    pediatric patients with active ERA/jPsA for whom routine treatment with secukinumab according to the approved national label is initiated during 4 to 8 weeks prior to enrollment

Primary Outcome Measure

Drug survival rate [ Time Frame: 24 months ]

Central Contacts

Related Studies